Multiple Myeloma Posts Page 2 on Medivizor
Navigation Menu

Multiple Myeloma Posts on Medivizor

Evaluating carfilzomib plus dexamethasone for newly diagnosed multiple myeloma

Posted by on Apr 23, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of the Kd regimen (carfilzomib, dexamethasone) for patients with newly diagnosed multiple myeloma. This study concluded that this regimen was effective for these patients, with mild side effects. Some background Multiple myeloma (MM) is a type of cancer of the bone marrow that...

Read More

Looking for patients with multiple myeloma to compare 2 conditioning regimens before stem cell transplantation

Posted by on Apr 22, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study is evaluating the effectiveness of melphalan (Alkeran) alone compared to BEAM chemotherapy (carmustine, etoposide, cytarabine, and melphalan) in patients with multiple myeloma before a stem cell transplant (SCT). The main outcome to be measured will be the number of patients who have complete disappearance of all signs of...

Read More

Evaluating ixazomib maintenance therapy for patients with multiple myeloma

Posted by on Apr 19, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of ixazomib (Ninlaro) given after a stem cell transplant for patients with multiple myeloma (MM). This study concluded that ixazomib maintenance therapy is effective for these patients, with manageable side effects. Some background Multiple myeloma is a type of cancer of the bone marrow...

Read More

Searching for patients to try a combination treatment for multiple myeloma.

Posted by on Apr 17, 2019 in Multiple Myeloma | 0 comments

In a nutshell The study will investigate the effects of carfilzomib (Kyprolis), pomalidomide (Pomalyst), and dexamethasone (Decadron) in multiple myeloma (MM). The main outcome that will be measured will be the percentage of patients who have no signs or symptoms of MM after treatment (completed response). This study is recruiting in Georgia, Unites...

Read More

A combination of clarithromycin, pomalidomide and dexamethasone in patients with relapsed/unresponsive multiple myeloma

Posted by on Apr 12, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of a combination of clarithromycin, pomalidomide, and dexamethasone (the ClaPd regime) in patients with relapsed/unresponsive multiple myeloma who had been treated with lenalidomide. This study concluded that this combination is as effective as other currently used...

Read More

Searching for patients with to try a new therapy for multiple myeloma.

Posted by on Apr 5, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study will investigate the effectiveness of daratumumab (Darzalex) added to VR-d regime [bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (Decadron)] versus VR-d alone in untreated multiple myeloma (MM). The development of minimal residual disease (MRD; a very small number of cancer cells remaining after treatment)...

Read More

The use of new agents and the risk of infections in patients with multiple myeloma

Posted by on Mar 29, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study aimed to investigate the use of newer agents and the risk of infections in patients with multiple myeloma. This study concluded that there is a high risk of these patients developing at least one infection during treatment. Some background Infections are a major cause of illness and death in patients with multiple...

Read More

Evaluating a treatment combination for patients with newly diagnosed and relapsed multiple myeloma

Posted by on Mar 28, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study aimed to investigate the combination D-VCd containing daratumumab (Darzalex), bortezomib (Velcade), cyclophosphamide (Cytoxan), and dexamethasone (Decadron) in patients with multiple myeloma. This study concluded that this combination was safe and effective for these patients. Some background...

Read More

Evaluating treatment options for patients with multiple myeloma who cannot have a stem cell transplant

Posted by on Mar 24, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the effectiveness of several treatment combinations for patients with multiple myeloma (MM) who were not eligible for a stem cell transplant (SCT). This study found that DaraVMP and VMPT were the most effective treatments for these patients. Some background MM is a type of cancer of the bone marrow that can lead...

Read More

Evaluating a new CAR-T cell therapy for patients with relapsed or refractory multiple myeloma

Posted by on Mar 10, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study investigated the safety and effectiveness of a new chimeric antigen receptor (CAR) T cell therapy for relapsed or refractory (does not respond to treatment) multiple myeloma (MM). This study found that this cell therapy was effective, but it had significant side effects.   Some background MM is a type of cancer of the...

Read More

Evaluating carfilzomib plus dexamethasone for relapsed or refractory multiple myeloma

Posted by on Mar 10, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the impact of carfilzomib (Kyprolis) and dexamethasone (Decadron) on quality of life for patients with relapsed or refractory (does not respond to treatment) multiple myeloma (MM). This study concluded that patients treated with this combination had a higher quality of life. Some background MM is a...

Read More

Searching for patients to try a new combination of treatments for multiple myeloma.

Posted by on Mar 5, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study will investigate the effectiveness of a new combination of chemotherapies: clarithromycin (Biaxin), lenalidomide (Revlimid) and dexamethasone (Decadron), for newly diagnosed multiple myeloma (MM). The main outcome that will be measured is survival without cancer worsening. This trial will take place in New York, the U.S....

Read More